Curaleaf Pushes Back After Alberta Regulator Rejects Challenge to Aurora’s Share Sales

Burn After Reading The 30-second intel for operators and investors ⏱ 0:30

Curaleaf says the Alberta Securities Commission's dismissal of its challenge to Aurora's share sales does not settle the hostile bid dispute. Its enhanced offer implies about $5 per Aurora share, an 86% premium, and expires December 4.

• Operators: The contest is unresolved, and Aurora's strategic review could still produce a competing deal. Operators who partner with or compete against either company should expect continued uncertainty, with no written ASC reasons yet published.
• Investors: The dismissal removes the immediate prospect of a halt to Aurora's ATM program, but the bid stays alive. Value depends on Curaleaf's share price, since the offer mixes cash and equity, and on whether a rival alternative emerges.
• Do now: Check the ASC proceeding record for written reasons and track the December 4 expiry, then compare the cash-and-equity offer against Aurora's stand-alone case before forming a view.

Short on time? You’re done. Want the numbers?Keep reading ↓

Curaleaf Holdings (TSX: CURA) (OTCQX: CURLF) is pushing back against an Alberta Securities Commission decision dismissing its challenge to Aurora Cannabis’ at-the-market (ATM) share issuance program, arguing that the regulatory setback does not resolve the central questions surrounding its hostile takeover bid.

In a statement issued Tuesday, October 27, Curaleaf Chairman and CEO Boris Jordan challenged Aurora’s interpretation of the ruling and renewed criticism of the company’s equity issuances, valuation arguments and refusal to provide Curaleaf with access to customary due diligence.

“Aurora would like shareholders to believe the ASC’s ruling changes the fundamental debate. It does not,” Jordan said.

The statement follows Aurora’s October 26 announcement that the commission had dismissed Curaleaf’s application to halt further share sales under its ATM program.

The Regulatory Decision

Curaleaf filed its application on September 14, alleging that Aurora’s share issuances diluted existing shareholders and interfered with their ability to evaluate its acquisition proposal.

The company previously estimated that Aurora’s ATM issuances had diluted shareholders by approximately 11% since the program began and increased the cost of its proposed acquisition by more than $11 million.

Aurora disputed that characterization, maintaining that the financing program was established in February 2026, months before Curaleaf launched its hostile bid, to provide flexibility for strategic investments, cultivation expansion and potential acquisitions.

The Alberta Securities Commission held a hearing on October 23 before a panel consisting of Kari Horn and Deanna Steblyk.

Aurora subsequently announced that the application had been dismissed, describing the result as confirmation of its position concerning the ATM program.

However, the commission’s publicly accessible proceeding record does not yet provide written reasons explaining the dismissal. The distinction matters: the outcome resolves Curaleaf’s application but does not establish whether the regulator examined or accepted every argument advanced by either company.

Curaleaf Questions Aurora’s Share Issuances

Curaleaf’s latest response focuses on the timing and pricing of Aurora’s equity sales.

According to Curaleaf, Aurora issued shares through the ATM program at prices as low as $2.56, substantially below the implied value of its enhanced takeover proposal.

The company also pointed to Aurora’s confirmation that it stopped using the program on August 18 and has not issued additional shares through it since.

Curaleaf argues that its regulatory challenge brought scrutiny to the program and helped protect shareholders against further dilution. That interpretation remains Curaleaf’s position rather than an established conclusion of the commission.

For shareholders, the economic issue extends beyond the legality of the financing program. Issuing additional equity increases the number of outstanding shares, potentially reducing existing investors’ percentage ownership and increasing the number of shares an acquirer must purchase.

An 86% Premium, but No Agreement on Value

The dispute over the ATM program comes amid a broader disagreement over Aurora’s valuation.

Curaleaf says its enhanced proposal implies approximately $5 per Aurora share, representing an 86% premium to Aurora’s unaffected volume-weighted average share price of approximately $2.75.

Jordan questioned why Aurora continues to describe the proposal as inadequate despite that premium.

Aurora’s board, however, maintains that the revised bid undervalues the company’s existing operations, international growth opportunities and balance-sheet assets.

The disagreement also reflects the structure of Curaleaf’s proposal, which includes both cash and Curaleaf shares. The ultimate value received by Aurora shareholders therefore depends partly on Curaleaf’s share price, rather than solely on a fixed cash payment.

A premium to historical trading prices does not necessarily settle the question of fair value, particularly when the consideration includes equity in another publicly traded company.

Due Diligence Becomes Another Point of Contention

Curaleaf also renewed its objections to Aurora’s strategic review process.

The company alleges that Aurora has provided other interested parties access to confidential information while continuing to exclude Curaleaf from customary due diligence.

Curaleaf argues that a process evaluating strategic alternatives should include a bidder that has already presented a public acquisition proposal.

Aurora, meanwhile, has maintained that its board and special committee are evaluating alternatives intended to maximize shareholder value.

The disagreement highlights a central tension in hostile acquisitions: a target board may pursue alternative transactions or remain independent, while a bidder seeks direct shareholder support without the target’s endorsement.

The Financial Stakes

Curaleaf continues to argue that combining the two companies would create a cannabis operator with operations across 17 countries, more than $1.5 billion in last-twelve-month revenue and nearly $350 million in adjusted EBITDA.

It also projects at least $40 million in annual cost synergies.

Those figures are company estimates and projections, not independently established post-merger results.

The potential combination would bring together Curaleaf’s substantial U.S. operations and Aurora’s international medical cannabis platform. It would also expose Aurora shareholders receiving Curaleaf equity to the combined company’s financial performance, capital structure, and regulatory risks.

Aurora has consistently argued that shareholders should evaluate those risks alongside the proposed premium.

What Happens Next?

The regulatory setback leaves Curaleaf’s acquisition effort intact, but it removes the immediate prospect of an ASC order suspending Aurora’s ATM program through the application that was dismissed.

Aurora continues to recommend that shareholders reject the revised hostile bid by taking no action.

Curaleaf, for its part, says it remains willing to engage directly with Aurora to pursue a negotiated transaction.

With the revised offer scheduled to expire on December 4, the contest now turns on shareholder support, the relative value of the proposed consideration and whether Aurora’s strategic review produces a competing alternative. Investors should contemplate whether or not Curaleaf’s combination of cash, equity, and projected synergies offers greater value than Aurora’s independent strategy or any alternative transaction.

The battle between Curaleaf and Aurora highlights the increasingly complex financial, regulatory, and strategic decisions shaping the cannabis industry’s next phase of consolidation. Want to discuss these developments face-to-face with the executives, investors and industry leaders navigating them? Join IgniteIt at the Cannabis Capital & Policy Summit in Washington, D.C., on November 18, where dealmaking, capital markets, federal policy, and the future of the cannabis industry will take center stage. Learn more and register here.